2019

1. The SRC inhibitor dasatinib induces stem cell-like properties in head and neck cancer cells that are effectively counteracted by the mithralog EC-8042

   Journal of Clinical Medicine, Vol. 8, Núm. 8

2. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

   American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899